Last Updated: May 10, 2026

Profile for Japan Patent: 2001270896


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Japan Patent: 2001270896

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Aug 17, 2027 Btg Intl VISTOGARD uridine triacetate
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Last updated: August 9, 2025

tailed Analysis of the Scope, Claims, and Patent Landscape for Japan Patent JP2001270896


Introduction

Japan Patent JP2001270896, filed in 2001, corresponds to a patent focused on a novel pharmaceutical invention. Understanding the scope, claims, and patent landscape surrounding this patent provides critical insights into its legal boundaries, technological breadth, and potential competitive positioning within the drug innovation sector. This analysis aims to dissect the patent’s claims, contextualize its scope, and explore its position within Japan's pharmaceutical patent landscape.


Patent Overview and Basic Details

  • Filing Date: December 21, 2001
  • Publication Date: October 19, 2001 (application publication date appears inconsistent, possibly a typo—likely 2002 or later)
  • Applicant: [Not specified; typically a pharmaceutical company or research entity]
  • Patent Number: JP2001270896
  • Status: Likely granted, considering its publication and enforceability

Note: The patent title and inventive specifics are not included in the provided data; an assumed focus based on typical pharmaceutical patent filings involves a novel chemical compound, formulation, or therapeutic use.


Scope of the Patent

The scope of Japan Patent JP2001270896 hinges on the patent claims, which define the invention's boundaries. Unlike the descriptive description, claims delineate exclusive rights.

Primary Focus of the Claims

While the full patent text is unavailable here, typical drug patents from similar filings in the early 2000s encompass:

  • Compound Claims: Covering novel chemical entities or derivatives.
  • Use Claims: Indicating specific therapeutic applications.
  • Formulation Claims: Detailing composition-specific aspects.
  • Method Claims: Outlining manufacturing or treatment methods.

Assuming JP2001270896 originates from this pattern, the scope likely includes:

  • Chemical structure claims with specific substituents.
  • Pharmacological activity claims, particularly targeting a disease or recommended condition.
  • Method of production for the compound.
  • Therapeutic claims defining the application in treating particular diseases.

Claim Types and Their Significance

  1. Composition/Compound Claims:
    These define the chemical entities covered, typically including structural formulas with allowable variations. The scope remains broad if multiple substituents or derivatives are disclosed using Markush groups.

  2. Use Claims:
    Claiming the application of the compound for specific treatments broadens protection. For example: treating a neurological disorder or certain cancers.

  3. Method and Process Claims:
    Covering manufacturing processes introduces plugin protection, potentially deterring competitors from uninfringing manufacturing.

  4. Formulation Claims:
    Addressing formulation-specific features can expand protection, especially if the invention involves novel delivery systems.

Implication:
A robust patent with broad claims could provide a significant monopoly over the specific chemical class or therapeutic method. Conversely, narrow claims limit scope but might be easier to defend or enforce.


Patent Landscape Analysis in Japan

Understanding the patent landscape entails exploring prior art, related patents, and patent family members.

Prior Art Considerations

  • Pre-2001 Publications:
    The scope is tested against prior art references, including earlier patents, scientific publications, and known compounds. An inventive step must be demonstrated over these.

  • Chemical Class and Novelty:
    If the compound belongs to a known class but introduces a unique substituent or pharmacological property, the patent emphasizes inventive step, not mere novelty.

Related Patent Families and Cumulative IP

  • Patent families in other jurisdictions, such as US and Europe, often parallel Japanese filings.
  • A global patent strategy may involve filing corresponding patents to secure broad international rights.

Patent Expiry and Potential Freedom-to-Operate (FTO)

  • Given the filing date, if granted, the patent's protection could last until 2021–2022 (a 20-year term from filing).
  • Possible expiry opens opportunities for generic development or licensing.

Legal and Strategic Considerations

  • Claim Interpretation:
    Japanese patent law emphasizes the "scope of the claims" during litigation, with courts interpreting claims based on language and equivalents.

  • Infringement Risks:
    Competitors must avoid infringing scope, including any equivalents or narrow claims.

  • Patent Validity Challenges:
    The patent could face oppositions or invalidation if prior art predates its filing or if it lacks an inventive step.

Competitive Landscape and Innovation Pipeline

  • Inhibitors and Competitors:
    Companies working on similar chemical classes or indications may have overlapping patents or ongoing R&D efforts.

  • Research Trends:
    The early 2000s experienced expansion in targeted therapies; if the patent pertains to such an area, many subsequent patents might cite or build upon it.

  • Patent Thickets:
    The development of combinatorial treatments may lead to overlapping patents that create barriers but also opportunities for licensing and collaboration.


Implications for Business and R&D

  • The scope and claims define the company's competitive advantage and market exclusivity.
  • Broader claims increase market control but may be more vulnerable to challenge; narrower claims offer limited protection but easier enforceability.
  • Understanding the patent’s position within Japan’s legal framework is essential for strategic planning, especially concerning licensing or entering generics.

Conclusion

Japan Patent JP2001270896 likely encapsulates a specific chemical entity, its use, and related manufacturing processes within its claims. Its scope depends heavily on claim language, potentially offering protection over a novel compound or therapeutic application. The patent landscape surrounding it encompasses prior art, related filings, and the broader technological field, with considerations for validity, infringement, and licensing strategies.

Period since filing and expiration status are critical for commercial decision-making. If still active, the patent constitutes a substantial barrier to market entry for similar compounds. If expired or challenged, opportunities arise for generic development or licensing negotiations.


Key Takeaways

  • A comprehensive review of the claims is vital to assess the scope of protection and identify potential overlaps with prior art.
  • Broad compound and use claims enhance market exclusivity but necessitate robust inventive step support.
  • The patent landscape must be analyzed to evaluate freedom-to-operate and identify potential licensing or infringement risks.
  • expiration timelines influence investment and R&D strategies; monitoring patent status is essential for timely decision-making.
  • Strategic management of patent rights, including filings in multiple jurisdictions, strengthens global competitiveness in pharmaceutical innovation.

FAQs

1. What is the typical process for challenging the validity of a patent like JP2001270896 in Japan?
Validity challenges often involve submissions to the Japan Patent Office (JPO) citing prior art or arguing lack of inventive step, followed by potential litigation in Japanese courts if the patent is enforced or contested.

2. How does claim scope affect licensing negotiations for pharmaceutical patents?
Broader claims can generate higher licensing revenue but pose higher invalidation risks; narrower claims ease enforcement but may limit royalty potential.

3. Can similar compounds be developed without infringing on JP2001270896?
Yes, if compounds differ significantly in structure or use, and do not fall within the patent claims, they can be developed without infringement—a process requiring detailed claim interpretation.

4. What strategies exist for extending patent protection beyond the original drug patent?
Strategies include filing for secondary patents, such as new formulations, methods of use, or manufacturing processes, to extend market exclusivity.

5. How do international patent laws influence the protection of drugs similar to what JP2001270896 covers?
International treaties like the Patent Cooperation Treaty (PCT) facilitate simultaneous applications in multiple countries, but each jurisdiction enforces its own patent laws, affecting scope, validity, and infringement considerations.


Sources:

[1] Japan Patent Office, Patent Data and Analysis.
[2] Patent Law of Japan, 2015 Edition.
[3] WIPO Patent Statistics and Analysis Reports.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.